



0040-4020(95)00121-2

Aplysillamides A and B, New Antimicrobial Guanidine Alkaloids from the Okinawan Marine Sponge *Psammaplysilla porea*

Kaori Honma, Masashi Tsuda, Yuzuru Mikami,^a and Jun'ichi Kobayashi*

Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060, Japan and

^aResearch Center for Pathogenic Fungi and Microbial Toxicoses, Chiba University, Chiba 260, Japan

Abstract: Two new guanidine alkaloids, aplysillamides A (**1**) and B (**2**), with antimicrobial activity have been isolated from the Okinawan marine sponge *Psammaplysilla porea* and the structures elucidated on the basis of spectroscopic data. The absolute stereochemistry at C-3 of **2** was established as *S* by synthesis of **2**.

A series of bioactive bromotyrosine-derived alkaloids has been isolated from the Okinawan marine sponge *Psammaplysilla porea*¹⁻⁴. Further investigation of extracts of this sponge led to isolation of two new guanidine alkaloids, aplysillamides A (**1**) and B (**2**) with antifungal and antibacterial activities. This paper describes the isolation, structure elucidation, and antimicrobial activity of **1** and **2**. The absolute configuration at C-3 of **2** was established by synthesis of **2**.

The EtOAc-soluble fraction of methanolic extract of this sponge, collected off Ishigaki Island, Okinawa, was subjected to a silica gel column (CHCl₃/*n*-BuOH/AcOH/H₂O, 1.5:6:1:1) followed by a C₁₈ column (MeCN/H₂O/CF₃CO₂H, 35:65:0.1) and reversed-phase HPLC (MeCN/H₂O/CF₃CO₂H, 42:58:0.1) to afford aplysillamides A (**1**, 0.002 %, wet weight) and B (**2**, 0.002 %).

HRFABMS data of aplysillamide A (**1**) provided the molecular formula, C₁₆H₃₂N₄O [*m/z* 297.2670, (M+H)⁺, Δ +1.6 mmu]. The presence of a guanidine moiety was elucidated by positive coloration to the Sakaguchi test as well as a quaternary carbon signal (δ_C 156.7) in the ¹³C NMR spectrum. The UV absorption {225 nm (ε 10000)}, IR band (1680 cm⁻¹), and carbon resonance at δ_C 165.7 were attributed to an α,β-unsaturated amide carbonyl group. The ¹H NMR spectrum of **1** showed proton signals due to two





Fig. 1. Structures of Aplysillamides A (**1**) and B (**2**) and EIMS Fragmentations of **1**



Scheme 1. Synthesis of Aplysillamide B (2)

(a) 1) DMSO, (COCl)₂, CH₂Cl₂, -78 °C, 30 min, then Et₃N; 2) Ph₃PC₆H₁₃Br, *n*-BuLi, THF, rt, 12 h;
 (b) Raney-Ni, H₂, EtOH, rt, 66 h; (c) 1) TsCl, Et₃N, DMAP, CH₂Cl₂, rt, 2 h; 2) NaCN, DMSO, 70 °C, 1 h;
 (d) NaOH, H₂O₂, EtOH, reflux, 22 h; (e) 1) HOSu, DCC, Dioxane, 4 °C, 20 h; 2) Agmatine Sulfate, THF-H₂O (1:1), rt, 44 h

NH (δ 7.75 and 7.57), an olefin (δ 5.60), a methyl (δ 1.75, 3H) on a double bond, a doublet methyl (δ 0.85, 3H), and ten methylenes [δ 3.07 (2H), 3.06 (2H), 2.58 (2H), 1.5 ~ 1.4 (6H), and 1.3 ~ 1.15 (8H)]. ¹H-¹H COSY cross-peaks, HMBC correlations, and EIMS fragmentations (Fig. 1) revealed the presence of a 4-(aminobutyl)guanidine (agmatine) moiety and a 3-methyl-2-decenoyl group. The HMBC correlation for H₂-1'/C-1 indicated that the agmatine moiety was attached at C-1 through an amide bond. *E*-Geometry of the double bond was ascertained by the NOESY cross-peak for H-2/H₃-11. Thus the structure of aplysillamide A was assigned to be **1**.

Aplysillamide B (**2**) was optically active $\{[\alpha]_D^{21} -2.4^\circ (c\ 0.1, \text{MeOH})\}$. HRFABMS data of **2** established the molecular formula, C₁₆H₃₄N₄O [m/z 299.2799, (M+H)⁺, Δ -1.2 mmu]. The ¹H and ¹³C NMR data implied that **2** was 2,3-dihydro form of aplysillamide A (**1**). In order to determine the absolute configuration at C-3 of aplysillamide B (**2**), **2** was synthesized as shown in Scheme 1. The alcohol (**3**); BOMO- = benzyloxymethoxy-) with *S*-configuration, which was prepared from methyl (2*R*)-3-hydroxy-2-methylpropionate, was applied to Swern oxidation and then Wittig reaction with hexylidene-triphenylphosphorane to afford the *E*-olefin (**4**). Reduction and deprotection of the olefin (**4**) with Raney-Ni in H₂ atmosphere gave the alcohol (**5**), which was converted into the cyanide (**6**) by tosylation followed by treatment with sodium cyanide in DMSO, and alkaline hydrolysis of **6** afforded the corresponding carboxylic acid (**7**). After esterification of **7** with *N*-hydroxysuccinimide (HOSu),^{5,6} the succinimidyl ester of **7** was condensed with agmatine to afford **2**, all spectral data of which were found to be identical with those of natural **2** including optical rotations {synthetic **2**, $[\alpha]_D^{22} -5.1^\circ (c\ 1.6, \text{MeOH})\}$. Thus the absolute configuration at C-3 of aplysillamide B (**2**) was concluded to be *S*.

Table 1. Antimicrobial Activities of Aplysillamides A (1) and B (2)

Compound	MIC values ($\mu\text{g/mL}$)									
	<i>C.alb</i>	<i>C.neo</i>	<i>P.var</i>	<i>A.nig</i>	<i>T.men</i>	<i>S.aur</i>	<i>S.lut</i>	<i>B.sub</i>	<i>E.coli</i>	<i>Myco</i>
1	133	66	33	133	33	16	16	66	133	66
2	133	33	16	66	33	16	16	66	133	33

Fungi: *Candida albicans*, *Cryptococcus neoformans*, *Paecilomyces variotii*, *Aspergillus niger*, and *Trichophyton mentagrophytes*.

Bacteria: *Staphyrococcus aureus*, *Sarcina lutea*, *Bacillus subtilis*, *Escherichia coli*, and *Mycobacterium* sp. 607.

Aplysillamides A (1) and B (2) are new antimicrobial guanidine alkaloids with a C₁₁ acyl chain from the sponge *Psammaphysilla porea*. To our knowledge, the isolation of alkaloids with an agmatine unit from marine sponges is very rare,⁷ although many guanidine alkaloids incorporating a homoagmatine unit have been reported.⁸⁻¹⁰ Compounds 1 and 2 exhibited modest antimicrobial activity against some fungi and bacteria as shown in Table 1. The comparison of antifungal activity of 1 and 2 indicated that reduction of the double bond at C-2 resulted in a slight increase in the activity. Aplysillamide A (1) was cytotoxic against murine lymphoma L1210 and human epidermoid carcinoma KB cells (IC₅₀ 5.5 and 5.8 µg/mL, respectively), while compound 2 showed no cytotoxicity (IC₅₀ > 10 µg/mL).

EXPERIMENTAL

Collection, Extraction, and Isolation. The dark brown sponge (1.5 kg, wet weight), *Psammaphysilla porea* Carter, was collected off Ishigaki Island, Okinawa, and kept frozen until used. The sponge was extracted with MeOH (1 L x 2). After evaporation of the solvent, the residue (55.6 g) was partitioned between EtOAc (500 mL x 3) and H₂O (500 mL). The EtOAc soluble material (3.30 g) was subjected to a silica gel column with CHCl₃/n-BuOH/AcOH/H₂O (1.5:6:1:1) and a C₁₈ column (Develosil LOP ODS 24S) with CH₃CN/H₂O/CF₃CO₂H (35:65:0.1) and then MeOH. The fraction (36.4 mg) eluting with MeOH was subjected to C₁₈ HPLC {YMC Pack AM323 ODS, 10 x 250 mm; eluent, CH₃CN/H₂O/CF₃CO₂H (42:58:0.1); flow rate, 2.5 mL/min; UV detection at 254 nm} to afford aplysillamides A (1, 3.2 mg, 0.002 %, wet wt, *t*_R 24.0 min) and B (2, 2.8 mg, 0.002 %, *t*_R 22.8 min).

Aplysillamide A (1). Colorless oil; UV (MeOH) λ_{max} 225 nm (ε 10000); IR (KBr) ν_{max} 3400, 2840, 1680, 1610, 1200, and 1130 cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 7.75 (1H, t, *J* = 5.5 Hz, NH-1), 7.57 (1H, br. s, NH-4'), 7.5 ~ 6.7 (3H, br., NH-5' and NH₂-5'), 5.60 (1H, s, H-2), 3.07 (2H, m, H₂-1'), 3.06 (2H, m, H₂-4'), 2.58 (2H, m, H₂-4), 1.75 (3H, s, H₃-11), 1.5 ~ 1.4 (6H, m, H₂-5, H₂-2', and H₂-3'), 1.3 ~ 1.15 (8H, m, H₂-6, H₂-7, H₂-8, and H₂-9), and 0.85 (3H, t, *J* = 6.6 Hz, H₃-10); ¹³C NMR (DMSO-*d*₆) δ 165.7 (s, C-1), 156.7 (s, C-5'), 152.1 (s, C-3), 119.2 (d, C-2), 40.4 (t, C-1'), 37.5 (t, C-4'), 31.8 (t, C-4), 31.2 (t), 29.0 (t), 28.5 (t), 27.5 (t), 26.4 (t), 26.0 (t), 24.2 (q, C-11), 22.0 (t, C-9), and 13.9 (q, C-10); EIMS *m/z* 296 (M)⁺, 281, 267, 253, 239, 225, 212, 199, 157, 130, 114, 100, 86, and 73; FABMS *m/z* 297 (M+H)⁺; HRFABMS (glycerol) *m/z* 297.2670 [(M+H)⁺, calcd for C₁₆H₃₃N₄O, 297.2654].

Aplysillamide B (2). Colorless oil; [α]_D²¹ -2.4° (c 0.1, MeOH); IR (KBr) ν_{max} 3400, 2840, 1680, 1610, 1200, and 1130 cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 7.79 (1H, t, *J* = 5.5 Hz, NH-1), 7.59 (1H, br. s, NH-4'), 7.5 ~ 6.7 (3H, br., NH-5' and NH₂-5'), 3.09 (2H, m, H₂-1'), 3.04 (2H, m, H₂-4'), 2.04 (1H, m, H-2), 1.85 (1H, m, H-2), 1.82 (1H, m, H-3), 1.41 ~ 1.10 (13H, m), 0.85 (3H, d, *J* = 7.3 Hz, H₃-11), and 0.82 (3H, t, *J* = 6.6 Hz, H₃-10); ¹³C NMR (DMSO-*d*₆) δ 170.8 (s, C-1), 156.7 (s, C-5'), 43.2 (t, C-2), 40.5 (t, C-1'), 36.2 (t, C-4'), 31.2 (t), 30.0 (d, C-3), 29.2 (t), 29.04 (t), 28.99 (t), 28.5 (t), 26.4 (t), 26.0 (t), 22.0 (t, C-9), 19.4 (q, C-11), and 13.9 (q, C-10) FABMS *m/z* 299 (M+H)⁺; HRFABMS (glycerol) *m/z* 299.2799 [(M+H)⁺, calcd for C₁₆H₃₅N₄O, 299.2811].

(3E,2S)-1-Benzoyloxymethoxy-2-methyl-3-nonene (4). To a solution of oxalyl chloride (0.66 mL, 7.6 mmol) in CH₂Cl₂ (13 mL) at -78 °C was slowly added DMSO (0.8 mL, 11.4 mmol) in CH₂Cl₂ (1 mL), and successively (2S)-3-benzoyloxymethoxy-2-methylpropan-1-ol (3 800 mg, 3.8 mmol), which was prepared from methyl (2R)-3-hydroxy-2-methylpropionate (commercially available), in CH₂Cl₂ (5.2 mL). After stirring at -78 °C for 30 min, Et₃N (2.5 mL, 18.5 mmol) was added to the reaction mixture, and stirring was continued at -50 °C for 1 h. After addition of saturated aqueous NH₄Cl and extraction with EtOAc, the organic phase was washed with H₂O and brine and dried over MgSO₄. Evaporation of the solvent afforded crude aldehyde, which was subjected to the following reaction without separation. To a solution of *n*-hexyltriphenylphosphonium bromide (2.2 g, 5.15 mmol) in THF (20 mL) at 0 °C was added a hexane solution of 1.6 M *n*-butyllithium (3.6 mL, 4.8 mmol). After stirring at 0 °C for 30 min, the crude aldehyde (700 mg) in THF (2 mL) was added dropwise to the reaction mixture at 0 °C, and stirring was continued for 12 h at room temperature. After addition of saturated aqueous NH₄Cl (30 mL), the reaction mixture was extracted with ether, washed with H₂O and then brine, and dried over MgSO₄. After evaporation, the residue was subjected to a silica gel column (hexane/EtOAc, 100:1) to give compound 4 (739 mg, 71 %): colorless oil; [α]_D²¹ +28° (c 0.38, CHCl₃); IR (neat) ν_{max} 2970, 2940, 2880, 1460, 1380, 1120, and 1050 cm⁻¹; ¹H NMR (CDCl₃) δ 7.36 ~ 7.26 (5H, m), 5.42 (1H, dt, *J* = 11.5 and 7.2 Hz), 5.19 (1H, dd, 9.1 and 11.5 Hz), 4.76 (2H, s), 4.60 (2H, s), 3.42 (2H, d, *J* = 6.3 Hz), 2.77 (1H, m), 2.06 (2H, m), 1.43 ~ 1.22 (6H, m), 1.00 (3H, d, *J* = 7.0 Hz), and 0.89 (3H, t, *J* = 6.7 Hz); FABMS *m/z* 277 (M+H)⁺; HRFABMS (3-nitrobenzyl alcohol) *m/z* 277.2180 (M⁺+H, calcd for C₁₈H₂₉O₂, 277.2168).

(2S)-2-Methylnonanol (5). To a solution of 4 (710 mg, 2.57 mmol) in EtOH (9 mL) at room temperature was added 50 % Raney-Ni W2 in EtOH (4 mL), and the mixture was stirred for 66 h under H₂ atmosphere. After filtration with celite, the solvent was evaporated to give a residue, which was purified by a

silica gel column (hexane/EtOAc, 3:1) to afford compound **5** (293.2 mg, 72 %): colorless oil; $[\alpha]_D^{21}$ -13° (c 0.5, CHCl₃); IR (neat) ν_{\max} 3300, 2960, 2930, 2850, 1460, 1380, and 1040 cm⁻¹; ¹H NMR (CDCl₃) δ 3.51 (1H, dd, $J = 5.9$ and 8.2 Hz), 3.41 (1H, dd, $J = 6.4$ and 8.2 Hz), 1.59 (1H, m), 1.43 ~ 1.22 (12H, m), 0.91 (3H, d, $J = 5.7$ Hz), and 0.88 (3H, t, $J = 6.9$ Hz); Anal. calcd for C₁₀H₂₂O: C 75.94, H 14.02; found C 75.09, H 14.02.

(3*S*)-3-Methyldecanenitrile (**6**). To a solution of **5** (288 mg, 1.8 mmol) in CH₂Cl₂, Et₃N (1.6 mL, 11.3 mmol), and 4-(dimethylamino)pyridine (33 mg, 0.27 mmol) at room temperature was added *p*-toluenesulfonyl chloride (688 mg, 3.6 mmol), and the mixture was stirred for 2 h. After addition of MeOH (0.5 mL), stirring was continued for 30 min at room temperature. The reaction mixture was partitioned between EtOAc and H₂O, and the organic layer was washed with brine and dried over MgSO₄. After evaporation, the residue was subjected to a silica gel column (hexane/EtOAc, 10:1) to give the tosylate (470 mg, 83 %). To a solution of the tosylate (462 mg, 1.49 mmol) in DMSO (10 mL) was added NaCN (219 mg, 4.46 mmol), and stirring was continued for 1 h at 70 °C. The reaction mixture was partitioned between EtOAc and H₂O, and the EtOAc layer was washed with brine, dried over MgSO₄, and evaporated. The crude product was subjected to a silica gel column (EtOAc/H₂O, 100:1) to give compound **6** (240 mg, 97%): colorless oil; $[\alpha]_D^{21}$ $+3.3^\circ$ (c 1.3, CHCl₃); IR (neat) ν_{\max} 2950, 2920, 2850, 2240, 1460, 1420, and 1380 cm⁻¹; ¹H NMR (CDCl₃) δ 2.31 (1H, dd, $J = 5.7$ and 16.7 Hz), 2.23 (1H, dd, $J = 9.3$ and 16.7 Hz), 1.84 (1H, m), 1.42 ~ 1.25 (12H, m), 1.08 (3H, d, $J = 6.7$ Hz), and 0.89 (3H, t, $J = 6.7$ Hz); EIMS m/z 167 (M⁺); HREIMS m/z 167.1646 (M⁺, calcd for C₁₁H₂₁N, 167.1674).

(3*S*)-3-Methyldecanoic acid (**7**). A solution of **6** (224 mg, 1.34 mmol) in EtOH (23 mL) containing NaOH (2.9 g, 72.5 mmol) was stirred at room temperature for 30 min. To the mixture was added 30 % aqueous H₂O₂ (23 mL), and the mixture was heated at refluxing temperature for 22 h. After addition of 1 M Na₂SO₃ (23 mL) and then 2 N HCl (80 mL), the reaction mixture was extracted with CH₂Cl₂, washed with brine, dried over MgSO₄, and evaporated to give compound **7** (234 mg, 94 %): colorless oil; $[\alpha]_D^{21}$ -5.8° (c 0.58, CHCl₃); IR (neat) ν_{\max} 3600 ~ 2400, 2970, 2940, 2860, 1710, 1470, 1420, 1300, 2130, and 950 cm⁻¹; ¹H NMR (CDCl₃) δ 2.35 (1H dd, $J = 5.9$ and 14.9 Hz), 2.14 (1H, dd, $J = 8.1$ and 14.9 Hz), 1.96 (1H, m), 1.32 ~ 1.23 (12H, m), 0.96 (3H, d, $J = 6.6$ Hz), and 0.88 (3H, t, $J = 6.9$ Hz); FABMS m/z 186 (M⁺); HRFABMS (3-nitrobenzyl alcohol) m/z 186.1633 (M⁺, calcd for C₁₁H₂₂O₂, 186.1620).

Synthesis of Aplysillamide **B** (**2**). To a mixture of **7** (229 mg, 1.23 mmol) and *N*-hydroxysuccinimide (177 mg, 1.53 mmol) in dioxane (4.5 mL) at 0 °C was added dicyclohexylcarbodiimide (289 mg, 1.40 mmol) in dioxane (2.2 mL), and stirring was continued at 4 °C in the dark for 20 h. After evaporation, the residue was dissolved in hexane/EtOAc. Insoluble material was filtered off, and then the filtrate was evaporated to give a crude *N*-hydroxysuccinimide ester (374 mg), which was subjected to the following reaction without purification. To a solution of agmatine sulfate (296 mg, 1.30 mmol) in H₂O (28 mL), which was adjusted to pH 8 with NaHCO₃, was added the crude *N*-hydroxysuccinimide ester (374 mg) in THF (28 mL). The mixture was left in the dark at room temperature for 44 h. The reaction mixture was partitioned between EtOAc and 1 N HCl, and the aqueous layer was neutralized by addition of 1N NaHCO₃, extracted with EtOAc, and evaporated. The crude product was purified by a Sep Pak C₁₈ column (MeOH/H₂O/CF₃CO₂H, 80:20:0.2) to afford **2** (53 mg, 13 %).

ACKNOWLEDGMENTS

We thank Prof. T. Sasaki, Kanazawa University, for the cytotoxicity test. This work was partly supported by a Grant-in-Aid from Ciba-Geigy Foundation (Japan) for the Promotion of Science and by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, and Culture of Japan.

REFERENCES

1. Tsuda, M.; Shigemori, H.; Ishibashi, M.; Kobayashi, J. *Tetrahedron Lett.*, **1992**, *33*, 2597-2598 and references cited therein.
2. Tsuda, M.; Shigemori, H.; Ishibashi, M.; Kobayashi, J. *J. Nat. Prod.*, **1992**, *55*, 1325-1327.
3. Kobayashi, J.; Honma, K.; Tsuda, M.; Kosaka, T. *J. Nat. Prod.*, in press.
4. Kobayashi, J.; Honma, K.; Sasaki, T.; Tsuda, M. *Chem. Pharm. Bull.*, in press.
5. Paquet, A. *Can. J. Chem.*, **1979**, *57*, 2775-2778.
6. Danklmaier, J.; Hönig, H. *Liebigs Ann. Chem.*, **1990**, 145-150.
7. Kourany-Lefoll, E.; País, M.; Sévenet, T.; Guittet, E.; Motagnac, A.; Fontaine, C.; Guénard, D.; Adeline, M. T.; Debitus, C. *J. Org. Chem.*, **1992**, *57*, 3832-3835.
8. Carter, G. T.; Rinehart, Jr., K. L. *J. Am. Chem. Soc.*, **1978**, *100*, 4302-4304.
9. De Nanteuil, G.; Ahond, A.; Guilhem, J.; Poupat, C.; Tran Huu Dan, E.; Potier, P.; Pusset, M.; Pusset, J.; Laboute, P. *Tetrahedron*, **1985**, *41*, 6019-6033.
10. Rodríguez, A. D.; Piña, I. C. *J. Nat. Prod.*, **1993**, *56*, 907-914.

(Received in Japan 12 January 1995; accepted 6 February 1995)